CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	True Up Costs December 2020	Avitide, Inc.	FlexBiosys, Inc.	Metenova Holding AB	Common Stock	Common Stock Avitide, Inc.	Common Stock FlexBiosys, Inc.	Common Stock Metenova Holding AB	Additional Paid-in Capital	Additional Paid-in Capital True Up Costs December 2020	Additional Paid-in Capital Avitide, Inc.	Additional Paid-in Capital FlexBiosys, Inc.	Additional Paid-in Capital Metenova Holding AB	Accumulated Other Comprehensive Income (Loss)	Accumulated Earnings/(Deficit)
Balance at Dec. 31, 2020	$ 1,529,150					$ 548				$ 1,460,748					$ 2,085	$ 65,769
Balance (in shares) at Dec. 31, 2020						54,760,837
Net Income (Loss)	128,291															128,291
Issuance of common stock for debt conversion	2					$ 0				2
Issuance of common stock for debt conversion (in shares)						7
Exercise of stock options and vesting of stock units	3,879					$ 3				3,876
Exercise of stock options and vesting of stock units (in shares)						300,721
Issuance of commons stock pursuant to the acquisition		$ 145	$ 82,968				$ 2				$ 145	$ 82,966
Issuance of commons stock pursuant to the acquisition, (in shares)							271,096
Tax withholding on vesting of restricted stock	(2,897)					$ 0				(2,897)
Tax withholding on vesting of restricted stock (in shares)						(11,204)
Stock-based compensation expense	27,500									27,500
Balance at Dec. 31, 2021	1,750,067					$ 553				1,572,340					(16,886)	194,060
Balance (in shares) at Dec. 31, 2021						55,321,457
Translation adjustment	(18,971)														(18,971)
Net Income (Loss)	185,959															185,959
Issuance of common stock for debt conversion	(6)					$ 1				(7)
Issuance of common stock for debt conversion (in shares)						21
Exercise of stock options and vesting of stock units	3,707					$ 3				3,704
Exercise of stock options and vesting of stock units (in shares)						326,192
Tax withholding on vesting of restricted stock	(17,018)					$ (1)				(17,017)
Tax withholding on vesting of restricted stock (in shares)						(89,972)
Stock-based compensation expense	27,316									27,316
Balance at Dec. 31, 2022	1,910,700					$ 556				1,547,266					(34,394)	397,272
Balance (Accounting Standards Update 2020-06) at Dec. 31, 2022	(21,817)									(39,070)						17,253
Balance (in shares) at Dec. 31, 2022						55,557,698
Translation adjustment	(17,508)														(17,508)
Net Income (Loss)	41,577															41,577
Issuance of common stock for debt conversion	(13)					$ 0				(13)
Issuance of common stock for debt conversion (in shares)						8
Exercise of stock options and vesting of stock units	1,076					$ 3				1,073
Exercise of stock options and vesting of stock units (in shares)						251,886
Repurchase of common stock	(14,386)					$ (1)				(14,385)
Repurchase of common stock (in shares)						(92,090)
Issuance of commons stock pursuant to the acquisition				$ 5,465	$ 8,104			$ 0	$ 1				$ 5,465	$ 8,103
Issuance of commons stock pursuant to the acquisition, (in shares)								31,415	52,299
Tax withholding on vesting of restricted stock	(13,227)					$ (1)				(13,226)
Tax withholding on vesting of restricted stock (in shares)						(77,759)
Issuance of common stock pursuant to the Avitide, Inc. contingent consideration earnout payment	7,229					$ 0				7,229
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment (in shares)						42,621
Stock-based compensation expense	25,575									25,575
Convertible note modification	2,791									2,791
Deferred tax impact on conversion feature	(651)									(651)
Balance at Dec. 31, 2023	1,971,203					$ 558				$ 1,569,227					(37,431)	$ 438,849
Balance (in shares) at Dec. 31, 2023						55,766,078
Translation adjustment	$ (3,037)														$ (3,037)